Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients
E. L. Choinzonov,
I. V. Reshetov,
S. A. Ivanov,
A. P. Polyakov,
M. A. Kropotov,
A. M. Mudunov,
V. V. Polkin,
P. A. Isaev,
A. A. Ilyin,
D. G. Beltsevich,
V. E. Vanushko,
P. O. Rumyantsev,
G. A. Melnichenko,
Yu. V. Alymov,
I. S. Romanov,
A. V. Ignatova,
E. V. Borodavina,
V. V. Krylov,
A. Yu. Shurinov,
N. V. Severskaya,
Z. A. Radjabova,
D. E. Kulbakin,
A. A. Nevolskikh,
A. R. Gevorkov,
E. V. Khmelevsky,
S. I. Kutukova,
A. O. Guz,
I. V. Sleptsov,
R. A. Chernikov,
A. M. Stepanova,
N. A. Falaleeva,
S. O. Podvyaznikov,
N. A. Rubtsova,
A. N. Rudyk,
Sh. I. Musin,
I. A. Gulidov,
L. Yu. Vladimirova,
T. Yu. Semiglazova,
T. A. Aghababyan,
E. V. Kostromina https://doi.org/10.14341/serg12792
Abstract
The article presents a draft of clinical recommendations for the diagnosis and treatment of differentiated thyroid cancer in adult patients, which provides a modern examination algorithm, discusses the basic principles of laboratory, instrumental diagnostics and treatment approaches.
About the Authors
E. L. Choinzonov
Tomsk National Research Medical Center; Siberian State Medical University
Evgeniy L. Choinzonov, MD, PhD, acad.
Tomsk
I. V. Reshetov
The State Education Institution of Higher Professional Training The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation
Igor V. Reshetov, MD, PhD, acad.
Moscow
S. A. Ivanov
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Sergei А. Ivanov, MD, PhD, Professor of the Russian Academy
of Sciences
Obninsk
A. P. Polyakov
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Andrey P. Polyakov, MD, PhD, docent
Moscow
M. A. Kropotov
Federal State Budgetary Scientific Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation
Mikhail A. Kropotov, MD, PhD
Moscow
A. M. Mudunov
Lapino Cancer Center
Ali M. Mudunov, MD, PhD, Professor of the Russian Academy
of Sciences
Lapino village
V. V. Polkin
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Vyacheslav V. Polkin, MD, PhD
Obninsk
P. A. Isaev
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Pavel A. Isaev, MD, PhD
Obninsk
A. A. Ilyin
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Alexey A. Ilyin, MD, PhD
Obninsk
D. G. Beltsevich
Endocrinology Research Centre
Dmitry G. Beltsevich, MD, PhD, Prof.
11 Dm. Ulyanova street, 117292 Moscow
V. E. Vanushko
Endocrinology Research Centre
Vladimir E. Vanushko, MD, PhD, Prof.
11 Dm. Ulyanova street, 117292 Moscow
P. O. Rumyantsev
International Medical Center “SOGAZ”
Pavel O. Rumyantsev, MD, PhD
Saint-Petersburg
G. A. Melnichenko
Endocrinology Research Centre
Galina A. Melnichenko, MD, PhD, Prof, acad.
Moscow
Yu. V. Alymov
Federal State Budgetary Scientific Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation
Yuri V. Alymov, MD, PhD
Moscow
I. S. Romanov
Federal State Budgetary Scientific Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation
Ilya S. Romanov, MD, PhD
Moscow
A. V. Ignatova
Federal State Budgetary Scientific Institution “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation; Peoples’ Friendship University of Russia
Anastasia V. Ignatova, MD, PhD
Moscow
E. V. Borodavina
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Ekaterina V. Borodavina
Obninsk
V. V. Krylov
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Valery V. Krylov, MD, PhD
Obninsk
A. Yu. Shurinov
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Andrey Yu. Shurinov
Obninsk
N. V. Severskaya
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Natalia V. Severskaya, MD, PhD
Obninsk
Z. A. Radjabova
Federal State Budget Institution «N.N. Petrov National Medical Research Centre of Oncology» Ministry of public health of Russian Federation
Zamira A. Radjabova, MD, PhD
Saint-Petersburg
D. E. Kulbakin
Tomsk National Research Medical Center
Denis E. Kulbakin, MD, PhD
Tomsk
A. A. Nevolskikh
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Alexey A. Nevolskikh, MD, PhD
Obninsk
A. R. Gevorkov
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Artem R. Gevorkov, MD, PhD
Moscow
E. V. Khmelevsky
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Evgeny V. Khmelevsky, MD, PhD, Prof.
Moscow
S. I. Kutukova
Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation; St. Petersburg State Institution City Clinical Oncological Dispensary
Svetlana I. Kutukova, MD, PhD, docent
Saint-Petersburg
A. O. Guz
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Alexander O. Guz, MD, PhD
Chelyabinsk
I. V. Sleptsov
N.I. Pirogov Clinic of High Medical Technologies of St. Petersburg State University, Saint-Petersburg; North-Western Center of Endocrinology and Endocrine Surgery
Ilya V. Sleptsov, MD, PhD, Prof.
Saint-Petersburg
R. A. Chernikov
N.I. Pirogov Clinic of High Medical Technologies of St. Petersburg State University
Roman A. Chernikov, MD, PhD
Saint-Petersburg
A. M. Stepanova
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Alexandra M. Stepanova
Moscow
N. A. Falaleeva
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Natalia A. Falaleeva, MD, PhD
Obninsk
S. O. Podvyaznikov
Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation
Sergey O. Podvyaznikov, MD, PhD, Prof.
Moscow
N. A. Rubtsova
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Natalia A. Rubtsova, MD, PhD
Moscow
A. N. Rudyk
Kazan State Medical Academy; Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Segal
Andrey N. Rudyk, MD, PhD
Kazan
Sh. I. Musin
State Autonomous Healthcare Institution Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Bashkortostan
Shamil I. Musin, MD, PhD
Ufa
I. A. Gulidov
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Igor A. Gulidov, MD, PhD, Prof
Obninsk
L. Yu. Vladimirova
Federal State Budgetary Scientific Institution “ National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation
Liubov Yu. Vladimirova, MD, PhD, Prof.
Rostov-on-Don
T. Yu. Semiglazova
Federal State Budget Institution «N.N. Petrov National Medical Research Centre of Oncology» Ministry of public health of Russian Federation
Tatiana Yu. Semiglazova, MD, PhD, docent
Saint-Petersburg
T. A. Aghababyan
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
Tatevik А. Aghababyan, MD, PhD
Obninsk
E. V. Kostromina
Federal State Budget Institution «N.N. Petrov National Medical Research Centre of Oncology» Ministry of public health of Russian Federation; Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation
Ekaterina V. Kostromina, MD, PhD
Saint-Petersburg
References
1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы: современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 448 с.
2. Каприн А.Д., Старинский В.В., А.О. Шахзадова, Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) – М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2022. − илл. − 252 с.
3. Allelein, S., Ehlers, M., Morneau, C., Schwartz, K., Goretzki, P., Seppel, T., … Schott, M. (2017). Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Hormone and Metabolic Research, 50(01), 23–28.
4. Матякин Е.Г., Подвязников С.О. Опухоли щитовидной железы. Онкология: справочник практикующего врача. Под ред. чл.-корр. РАН И.В. Поддубной. М.: МЕДпресс-информ, 2009. C. 177–185.
5. Бржезовский В.Ж. Опухоли щитовидной железы. Опухоли головы и шеи. 5-е изд., доп. и перераб. М.: Практическая медицина, 2013. С. 339–359.
6. Бельцевич Д.Г., Ванушко В.Э., Румянцев П.О. и др. Российские клинические рекомендации по диагностике и лечению высокодифференцированного рака щитовидной железы у взрослых. Эндокринная хирургия 2017;1(11):6–27.
7. Алиева С.Б., Алымов Ю.В., Кропотов М.А. и др. Рак щитовидной железы. Онкология. Клинические рекомендации. Под ред. М.И. Давыдова. М.: Издательская группа РОНЦ, 2015. C. 538–547.
8. Злокачественные опухоли головы и шеи. Под ред. Подвязникова С.О., Мудунова А.М., Болотина М.В. и др. Клинические рекомендации по лечению опухолей головы и шеи Общенациональной онкологической сети (США). М.: ООО «АБВ-пресс», 2019.
9. Онкология. Клинические рекомендации. Под ред. В.И. Чиссова. М.: ГЭОТАР-Медиа, 2006. C. 125–139.
10. Cooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109–42.
11. McLeod D.S., Watters K.F., Carpenter A.D. et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012;97:2682–92. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22622023.
12. Rinaldi S., Plummer M., Biessy C. et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 2014;106:dju097. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24824312.
13. Bonavita J.A., Mayo J., Babb J. et al. Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? AJR Am J Roentgenol 2009;193:207–13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19542415.
14. Alexander E.K., Cooper D. The importance, and important limitations, of ultrasound imaging for evaluating thyroid nodules. JAMA Intern Med 2013;173:1796–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23979653.
15. Friedrich-Rust M., Meyer G., Dauth N. et al. Interobserver agreement of Thyroid Imaging Reporting and Data System (TIRADS) and strain elastography for the assessment of thyroid nodules. PLoS One 2013;8:e77927. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24205031.
16. Kamran S.C., Marqusee E., Kim M.I. et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013;98:564–70. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23275525.
17. Yang J., Schnadig V., Logrono R., Wasserman P.G. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 2007;111:306–15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17680588.
18. DANESE, D., SCIACCHITANO, S., FARSETTI, A., ANDREOLI, M., & PONTECORVI, A. (1998). Diagnostic Accuracy of Conventional Versus Sonography-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Thyroid, 8(1), 15–21.
19. Trimboli, P., D’Aurizio, F., Tozzoli, R., & Giovanella, L. (2017). Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clinical Chemistry and Laboratory Medicine (CCLM), 55(7).
20. Cibas E.S., Ali S.Z. The 2017 Bethesda System For Reporting Thyroid Cytopathology. Thyroid 2017;27:1341–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29091573.
21. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Thyroid Carcinoma. Version 2.2022.
22. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9374215.
23. Matsuzu K., Sugino K., Masudo K. et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014;38:68–79. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24081532.
24. Francis G, Waguespack S, Bauer A, et al. American Thyroid Association Guidelines Task Force Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul;25(7):716-59. doi: 10.1089/thy.2014.0460
25. Danielle L., James MB, MCh. et al. Radioiodine Remnant Ablation for Differentiated Thyroid CancerA Systematic Review and Metaanalysis. JAMA Otolaryngol Head Neck Surg. 2021;147(6):544-552. doi:10.1001/jamaoto.2021.0288
26. Каприн А.Д.. Терапевтическая радиология. Национальное руководство. М.-2018г.-С.640-651.
27. Шуринов А.Ю., Крылов В.В., Бородавина Е.В. Радиойодаблация при раке щитовидной железы. Исторические и современные аспекты. Обзор литературы. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021;4(4):9-19. https://doi.org/10.37174/2587-7593-2021-4-4-9-19
28. Filetti S, Durante C, Hartl D, et al. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019. Dec1 ;30(12): 1856-1883. doi: 10.1093/annonc/mdz400.
29. Vrachimis A, Riemann B, Mäder U, et al. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):224-231. doi: 10.1007/s00259-015-3223-2.
30. Gulec S, Ahuja S, Bernet V, et al. A Joint Statement from the American Thyroid Association,the European Association of Nuclear Medicine, the EuropeanThyroid Association, the Society of Nuclear Medicineand Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid. 2021 Jul;31(7):1009-1019. doi: 10.1089/thy.2020.0826.
31. Francis G, Waguespack S, Bauer A, et al. American Thyroid Association Guidelines Task Force Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul;25(7):716-59. doi: 10.1089/thy.2014.0460.
32. Biondi B., Cooper D.S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;20:135–46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20151821.
33. Brose M.S., Worden F.P., Newbold K.L., Guo M., Hurria A. Влияние возраста пациентов на эффективность и безопасность ленватиниба при лечении радиойодрефрактерного дифференцированного рака щитовидной железы в исследовании III фазы SELECT. Опухоли головы и шеи. 2018;8(2):39-52. https://doi.org/10.17650/2222-1468-2018-8-2-39-52.
34. Brose M.S., Panaseykin Y., Konda B., de la Fouchardiere C., Hughes B.G., Gianoukakis A.G., Park Y.J., Romanov I., Krzyzanowska M.K., Leboulleux S., Binder T.A., Dutcus C., Xie R., Taylor M.H. Рандомизированное исследование по оценке безопасности и эффективности двух дозировок ленватиниба – 18 и 24 мг – у пациентов с радиойодрефрактерным дифференцированным раком щитовидной железы. Опухоли головы и шеи. 2022;12(1):86-98. https://doi.org/10.17650/2222-1468-2022-12-1-86-98
35. Schlumberger, M., Tahara, M., Wirth, L. J., et al. (2015). Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 372(7), 621–630. doi:10.1056/nejmoa1406470
36. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319-328. doi:10.1016/S0140-6736(14)60421-9.
37. Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(8):1126-1138. doi:10.1016/S1470-2045(21)00332
38. Mosele, F., Remon, J., Mateo, J., et al (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. doi:10.1016/j.annonc.2020.07
39. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739
40. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271–282. doi: 10.1016/S1470-2045(19)30691-6
41. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637–42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9360519.
42. Expert Panel on Radiation Oncology-Bone Metastases, Lo S.S., Lutz S.T. et al. ACR Appropriateness Criteria (R) spinal bone metastases. J Palliat Med 2013;16:9–19. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23167547.36.
43. Breelyn A Wilky , David M Loeb. Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP. Clin Exp Pharmacol. 2013 Jun;3(3):1000131. doi: 10.4172/2161-1459.1000131
44. Reyhaneh Manafi-Farid , Fardad Masoumi , Ghasemali Divband , Bahare Saidi , Bahar Ataeinia, Fabian Hertel , Gregor SchweighoferZwink , Agnieszka Morgenroth , Mohsen Beheshti. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. J Clin Med. 2020 Aug 12;9(8):2622. doi: 10.3390/jcm9082622
45. Nicole M. Iñiguez-Ariza,a,b Keith C. Bible,c, and Bart L. Clarkea. Bone metastases in thyroid cancer. J Bone Oncol. 2020 Apr; 21: 100282. Published online 2020 Feb 19. doi: 10.1016/j.jbo.2020.100282
46. Fernanda Andrade , Danielle Probstner , Marcus Decnop , Daniel Bulzico , Denise Momesso , Rossana Corbo , Mario Vaisman , Fernanda Vaisman. The Impact of Zoledronic Acid and Radioactive Iodine Therapy on Morbi-Mortality of Patients with Bone Metastases of Thyroid Cancer Derived from Follicular Cells. Eur Thyroid J. 2019 Jan;8(1):46-55. doi: 10.1159/000493190. Epub 2018 Oct 3.
47. Juan Lv , Fu-Kun Chen , Chao Liu , Peng-Jie Liu , Zhi-Ping Feng, Li Jia, Zhi-Xian Yang , Fei Hou , Zhi-Yong Deng. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/βcatenin pathway. Life Sci. 2020 Sep 1;256:117925. doi: 10.1016/j. lfs.2020.117925. Epub 2020 Jun 6.
48. Mosele, F., Remon, J., Mateo, J., et al (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. doi:10.1016/j.annonc.2020.07
49. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406-415. doi:10.1016/j.annonc.2021.12.014
50. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations . N Engl J Med. 2015;373(8):726-736. doi:10.1056/nejmoa1502309
51. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739.
52. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271–282. doi: 10.1016/S1470-2045(19)30691-6
53. Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021;31(3):337-386. doi:10.1089/thy.2020.0944
54. Никифорович П.А., Поляков А.П., Слепцов И.В. и др. Таргетная терапия анапластического рака щитовидной железы. Опухоли головы и шеи 2022;12(4):20–25. DOI: 10.17650/2222-1468-2022-12-4-00-00
55. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol. 2001;27(3):260-264. doi:10.1053/ejso.2000.1098
56. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol. 2010;22(6):486-497. doi:10.1016/j.clon.2010.03.013
57. Lee DY, Won J-K, Choi HS, et al. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma. Thyroid. 2016;26(9):1259-1268. doi:10.1089/thy.2016.0147
58. Pozdeyev N, Gay LM, Sokol ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24(13):3059-3068. doi:10.1158/1078-0432.CCR-18-0373
59. Rao SN, Zafereo M, Dadu R, et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017;27(5):672-681. doi:10.1089/thy.2016.0395
60. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014;12(7):979-986. doi:10.1158/1541-7786.MCR-14-0158-T
61. McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(16). doi:10.1073/pnas.1404357111
62. Long G V., Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014;371(20):1877-1888. doi:10.1056/nejmoa1406037
63. Nikiforovich PA, Rumiantsev PA, Sleptsov I V., et al. Treatment of BRAFv600e positive anaplastic thyroid carcinoma: Case report. Sib J Oncol. 2020;19(5):131-144. doi:10.21294/1814-4861-2020-19-5-131-144
64. Long G V., Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/ K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631-1639. doi:10.1093/annonc/mdx176
Supplementary files
|
|
1. Рисунок. Алгоритмы действий врача | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(197KB)
|
Indexing metadata ▾ | |
Review
For citations:
Choinzonov E.L., Reshetov I.V., Ivanov S.A., Polyakov A.P., Kropotov M.A., Mudunov A.M., Polkin V.V., Isaev P.A., Ilyin A.A., Beltsevich D.G., Vanushko V.E., Rumyantsev P.O., Melnichenko G.A., Alymov Yu.V., Romanov I.S., Ignatova A.V., Borodavina E.V., Krylov V.V., Shurinov A.Yu., Severskaya N.V., Radjabova Z.A., Kulbakin D.E., Nevolskikh A.A., Gevorkov A.R., Khmelevsky E.V., Kutukova S.I., Guz A.O., Sleptsov I.V., Chernikov R.A., Stepanova A.M., Falaleeva N.A., Podvyaznikov S.O., Rubtsova N.A., Rudyk A.N., Musin Sh.I., Gulidov I.A., Vladimirova L.Yu., Semiglazova T.Yu., Aghababyan T.A., Kostromina E.V. Draft of clinical guidelines for the diagnosis and treatment of differentiated thyroid cancer in adult patients. Endocrine Surgery. 2022;16(2):5-29. (In Russ.) https://doi.org/10.14341/serg12792
Views:
5533
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
